ACR Convergence 2021

November 5-9, 2021. All Virtual.

View by Number View by Title View Sessions

View by Date

Monday, November 8, 2021

8:30AM-10:30AM: Abstract Number: 1249

In Rheumatoid Arthritis, Inhibition of the Lactate Monocarboxylate Transporters-1, and -4 in Pathological Fibroblast-Like Synoviocytes Led to Decreased ChemokineProduction

RA – Treatments Poster II: PROs, Biomarkers, & Systemic Inflammation (1223–1256)

8:30AM-10:30AM: Abstract Number: 1406

Incidence and General Clinical Features of Giant Cell Arteritis in the ARTESER Multicenter Study

Vasculitis – Non-ANCA-Associated & Related Disorders Poster I: Giant Cell Arteritis & Polymyalgia Rheumatica (1391–1419)

8:30AM-10:30AM: Abstract Number: 1022

Incidence of Antisynthetase Syndrome and Risk of Malignancy in a Population-based Cohort (1998-2019)

Epidemiology & Public Health Poster III: Other Rheumatic & Musculoskeletal Diseases (1022–1060)

8:30AM-10:30AM: Abstract Number: 1304

Increased Risk of Vertebral Fracture Among Patients with Psoriatic Arthritis: A Systematic Review and Meta-analysis

Spondyloarthritis Including PsA – Diagnosis, Manifestations, & Outcomes III: Comorbidities, Extra-muskuloskeletal Manifestations, & Related Conditions (1304–1328)

8:30AM-10:30AM: Abstract Number: 0998

Increasing Age Impairs the Metabolic Adaptation of Human Neutrophils to Glucose Deprivation

Innate Immunity Poster (0992–1006)

8:30AM-10:30AM: Abstract Number: 0992

Inflammatory Arthritis in HIV-Infected Humanized Mice

Innate Immunity Poster (0992–1006)

8:30AM-10:30AM: Abstract Number: 0995

Innate Immune Tolerance Attenuates Zymosan-Induced Arthritis, Inflammatory Gene Expression and Synovial Neutrophil Infiltration

Innate Immunity Poster (0992–1006)

8:30AM-10:30AM: Abstract Number: 1128

Inter-relationships Between Multiple Joint Osteoarthritis and Collagen Biomarkers in Men: The Johnston County Osteoarthritis Project

Osteoarthritis – Clinical Poster III (1118–1134)

8:30AM-10:30AM: Abstract Number: 1131

Interleukin 6 Concentration in Synovial Fluid and Its Clinical Significance

Osteoarthritis – Clinical Poster III (1118–1134)

8:30AM-10:30AM: Abstract Number: 1318

Interplay Between Covid-19 and Spondyloarthritis or Its Treatment

Spondyloarthritis Including PsA – Diagnosis, Manifestations, & Outcomes III: Comorbidities, Extra-muskuloskeletal Manifestations, & Related Conditions (1304–1328)

8:30AM-10:30AM: Abstract Number: 1191

Introduction of a Joint Injection and Ultrasound Workshop for Internal Medicine Trainees

Professional Education Poster (1170–1195)

8:30AM-10:30AM: Abstract Number: 1187

Is Your Program Website Optimized for Recruitment? An Evaluation of Rheumatology Fellowship Program Websites

Professional Education Poster (1170–1195)

8:30AM-10:30AM: Abstract Number: 1347

Ixekizumab Efficacy in Patients with Psoriatic Arthritis Presenting with Symptoms Indicative of Axial Involvement

Spondyloarthritis Including PsA – Treatment Poster II: Psoriatic Arthritis I (1329–1363)

8:30AM-10:30AM: Abstract Number: 1341

Ixekizumab Shows a Pattern of Pain Improvement in Patients with and Without Measurable Inflammation in Psoriatic Arthritis

Spondyloarthritis Including PsA – Treatment Poster II: Psoriatic Arthritis I (1329–1363)

8:30AM-10:30AM: Abstract Number: 1018

Joint-Draining Popliteal Lymphatic Vessels Exhibit Lymphatic Muscle Cell Dysfunction in TNF-Tg Mice with Inflammatory Arthritis

RA – Animal Models Poster (1014–1021)

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].